CBDWorldNews Editorial Staff | May 16, 2026
State Cannabis Regulator Steps Into Clinical Research
New York’s Office of Cannabis Management (OCM) announced a pilot study examining oral CBD and THC dosing in adults with inflammatory bowel disease. The initiative marks the first time a state regulatory agency has directly led a cannabis clinical trial rather than simply funding university-based research.
The study — formally titled “A Pilot Prospective Observational Study to Assess the Effects of Cannabidiol (CBD) and Delta-9-Tetrahydrocannabinol (THC) on Inflammatory Bowel Disease Symptoms” — partners the OCM with two licensed dispensary operators.
“This study represents what state-level cannabis regulation should look like: generating real clinical data while providing supervised access to patients who need options.” — OCM announcement
Study Design and Partners
Vireo Health, a physician-founded cannabis company, and RISE Dispensaries, a multi-state chain with six New York locations, will collaborate on patient recruitment and product supply.
Participants must be at least 18 years old with a clinically confirmed IBD diagnosis. The screening process requires participants to abstain from smoked marijuana for the study’s duration. The study focuses specifically on oral dosing — an important distinction that aligns with the CBD product formats most consumers already use.
The observational design means researchers will track outcomes in patients using commercially available products under clinical supervision, rather than conducting a traditional randomized controlled trial with placebo groups.
Why IBD Matters for CBD Research
Inflammatory bowel disease affects approximately 3 million American adults, encompassing Crohn’s disease and ulcerative colitis. Current treatments include immunosuppressants, biologics, and corticosteroids — all carrying significant side effect profiles.
A separate study published earlier this year found that 87.5% of IBD patients already using CBD reported symptom relief. That survey data, published in the journal JGH Open, examined self-reported outcomes from a gastroenterology outpatient population.
But self-reported surveys carry well-known limitations. New York’s study aims to generate more structured observational data under medical supervision, bridging the gap between anecdotal reports and the rigorous clinical trials the FDA requires for drug approval.
The Broader Research Landscape
The study arrives during a productive year for CBD research. Over 70 cannabis-related studies have been published in 2026 covering pain relief, oncology, brain injury, sleep, metabolism, inflammation, and wound healing.
Not all findings have been positive. A 2026 Cochrane Review of 21 studies involving 2,187 participants found no clear evidence that CBD-dominant medicines achieve meaningful neuropathic pain relief. A separate systematic review of anxiety studies found contradictory results across different disorders and dosing protocols.
These mixed findings underscore why additional structured studies — like New York’s IBD trial — remain critical. The CBD market has grown faster than the research base supporting it, leaving both consumers and clinicians navigating uncertainty.
What This Means for Patients
New Yorkers with IBD interested in participating can find information at cannabis.ny.gov/ibd-study-2026. The study offers medical supervision for patients curious about CBD but hesitant to self-medicate without clinical guidance.
For the broader CBD industry, state-led research legitimizes the product category in ways that privately funded studies cannot. State agencies carry institutional credibility that matters to physicians, insurers, and regulators.
Companies selling CBD products marketed for digestive wellness should note that this study may eventually provide — or disprove — clinical backing for their marketing claims. Either outcome advances the field. Understanding lab testing and product quality remains essential for consumers regardless of research outcomes.
These statements have not been evaluated by the Food and Drug Administration. CBD products are not intended to diagnose, treat, cure, or prevent any disease.
